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Dymaxium Inc., Toronto, Ontario , Canada, 2 Dymaxium Inc., Toronto, Ontario, Canada, 3 Amgen, Zug, Switzerland, 4 Amgen GmbH, Munich, Germany OBJECTIVES: From a German health care perspective, to evaluate the cost per patient in achieving KDOQI TM targets with the use of a combination of cinacalcet traditional therapy (TT) . METHODS: The number of patients eligible for cinacalcet was derived from the OPen-label, Randomized Study Using Cinacalcet HCL To IMprove Achievement of KDOQI TM Targets in Patients With End-Stage Renal Disease (OPTIMA) Trial [1] , assessing the efficacy of adding cinacalcet to a TT protocol in controlling bone metabolic parameters in dialysis patients with secondary hyperparathyroidism over a 23-week period. KDOQI TM targets considered are: iPTH 300 pg/mL, calcium (Ca) 9.5 mg/dL and phosphorus (P) 5.5 mg/dL. Resource utilization included the average dose per day, average duration of therapy, and cost per dose. The model compares the cost per patient who achieves target and the cost per week to maintain target, with the use of a combination of cinacalcet TT relative to TT alone or no therapy. RESULTS: At the end of the study period, 30.2% (111) of patients receiving cinacalcet TT achieved their KDOQI TM targets, compared with 2.7% (5) for TT. The average cost per week of maintaining target was a349.10 for patients on cinacalcet TT and a597.29 for patients on TT. The incremental cost per incremental week in target was a491.40 with TT compared with no therapy and was cost-saving (minus 39.68a per week) with cinacalcet TT. The incremental cost per incremental patient at target after 23 weeks was a5,895.06 for patients receiving cinacalcet TT compared with TT and a36,991.66 for patients receiving TT compared with no therapy. CONCLU-SIONS: Patients administered cinacalcet TT maintain, on average, KDOQI TM targets longer than patients receiving TT and require less resources. This translates into lower costs per patient (compared with TT) to achieve and maintain KDOQI TM targets. 1. Messa et al. Clin J Am Soc Nephrol. 2008; 3:36-45 .
PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS
Goeree RA, Lim ME, Hopkins R, Blackhouse G, Tarride JE, Xie F, O'Reilly D McMaster University, Hamilton, ON, Canada OBJECTIVES: Costing studies often do not identify the excess costs incurred by the health care system for patients with a disease vs. patients without the disease. Using cohort based cost estimates without controlling for costs also incurred by a nondisease population can bias projections, long-term modeling and economic evaluation analyses. The objective of this study was to estimate the prevalence, total and excess costs attributable to diabetes and its complications in Ontario, Canada over 11 years (1995 to 2005) . METHODS: Newly diagnosed type 1 and 2 diabetes cases aged 35 and over were identified from the Ontario Diabetes Database and matched 1:2 using propensity scores with controls (non-diabetes cases). The following complications were identified: myocardial infarction, stroke, angina, heart failure, blindness in 1 eye, amputation, nephropathy and cataracts. Excess costs of diabetes were estimated as the difference between costs attributed to patients with diabetes vs. those attributed to patients without diabetes. RESULTS: The prevalence of diabetes rose drastically, from 6.5 to 10.5%. Excess costs were $2930 in the year of diabetes diagnosis and $1240 in subsequent years. In the year of an event, cost differences were greatest for patients with diabetes who had an amputation ($5133), followed closely by nephropathy ($4117) and stroke cases ($3965). Excess costs were apparent for both females and males, and the cost amount was strongly associated with increasing age. CON-CLUSIONS: Results demonstrate that relying on costs from a population with only the disease (i.e. diabetes) with no control can overestimate costs of the disease and associated complications. Assessing excess costs of disease is important for costing studies, longer-term modeling and economic evaluations in general. Existing studies which do not account for excess cost may overestimate cost and potentially bias estimates of cost-effectiveness or cost savings due to effective patient management.
PDB22 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) FOR TYPE 2 DIABETES PATIENTS ON ORAL ANTI-DIABETES DRUGS (OADS): COST-EFFECTIVENESS IN FRANCE, GERMANY, AND SPAIN
Tunis S 1 , Willis WD 2 1 IMS Consulting Services, Falls Church, VA, USA, 2 LifeScan, Inc., High Wycombe, Bucks, UK OBJECTIVES: Stakeholders in Europe remain keenly interested in obtaining information to help assess country-specific value of SMBG for patients with type-2 diabetes and treated with OADs. From national reimbursement system perspectives in France, Germany, and Spain, this study modeled the long-term (40-year) cost-effectiveness of SMBG at 1, 2, or 3x/day (vs. no SMBG) for this patient population. METHODS: SMBG input costs (strips, lancets, monitors, nurse training) were supplied by LifeScan in a2007 values and applied as appropriate for each country's current reimbursement policy. Cohort characteristics and assumed HbA1c effects came from a U.S. Kaiser Permanente longitudinal analysis of new SMBG users. Country-specific complication costs obtained from published sources were inflated to a2007 values. Base-case outcomes were discounted at 3% per annum for France and Germany; 6% for Spain. Sensitivity analyses varied time horizon (5, 10, 20 years) and discount rates relevant to each country. Sensitivity analyses also included a 0.036 dis-utility for SMBG in year 1. RESULTS: Incremental cost-effectiveness ratios (ICERs) were largest in France, where monitors were included as reimbursed SMBG acquisition costs. ICERs for SMBG 1x, 2x, and 3x/day were a12,114, a6,282, and a7,958, respectively. ICERs for SMBG 1 or 2x/day were a2,000 in Germany and a4,000 in Spain. ICERs for SMBG 3x/day were a6000/QALY in both countries. Results were most sensitive to the 5-year time horizon. With the SMBG dis-utility, ICERs increased only modestly (a321-a2264/QALY) in all scenarios except SMBG 1/day in France, where it increased by a9578. CONCLUSIONS: With SMBG cost assumptions reflecting current payer reimbursement in France, Germany, and Spain, the use of SMBG was found to be costeffective. This study adds to the literature on the impact of assuming an SMBG dis-utility, and on the country-specific, long-term value of SMBG as a management tool for type-2 diabetes patients treated with OADs.
PDB23 PREDICTING COST-EFFECTIVENESS OF A DIABETES HEALTH CARE PROGRAM IN BELGIUM AS A POLICY MANAGEMENT TOOL
Benoit K 1 , Bastiaens H 2 , Sunaert P 1 , Annemans L 1 1 Ghent University, Ghent, Belgium, 2 Antwerp University, Wilrijk, Belgium OBJECTIVES: Diabetes type 2 is a major health problem with severe complications and a significant impact on quality of life. International guidelines, developed to provide better care and to prevent complications, are difficult to translate into daily practice. Especially the lack of prevention of retinopathy and nephropathy through frequent screening are a current concern. The aim of this study is to assess the minimum impact a program at a pre-specified policy defined cost, supporting general practitioners to put recommendations into daily clinical practice, has to achieve to be cost-effective. METHODS: We estimated the minimum number of patients, with a mean age of 65 years, that should be screened annually for respectively retinopathy and nephropathy, for the program at an implementation cost of a195 per patient, to to be cost-effective. For both complications, a Markov model, adapted from published peer-reviewed models, was developed simulating the evolution of a patients cohort with type 2 diabetes over 25 years with cycles of 1 year. A public health care payer perspective in a Belgian setting was chosen. Transition probabilities were obtained from local epidemiological studies and published trials. Cost data of the different states were collected from literature and from the National Institute for Health and Disability Insurance. Utility data for all states were obtained from published studies. A ratio of a30,000/QALY was used as threshold of willingness to pay for health gain. RESULTS: We found for nephropathy a net-saving cost of a6500/QALY when there is only an increase in annual screening of 10%. For retinopathy we found a net price of a1005 but no health gain. CONCLUSIONS: A scientific program in a Belgian setting with a given implementation cost of a195 per patient and a minimum increase in screening in the intervention group, would be cost-effective in the prevention of nephropathy and retinopathy.
PDB24 COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING
Suchankova E 1 , Doležal T 1 , Pisarikova Z 1 , Rychna K 2 , Bartaskova D 3 1 Charles University, Prague , Czech Republic, 2 Novo Nordisk s.r.o, Praha 6, Czech Republic, 3 2nd Medical faculty Charles University, Prague, Czech Republic OBJECTIVES: The aim of this health economic analysis was to assess the cost-effectiveness of biphasic insulin aspart (BIAsp) when switched from biphasic human insulin 30 (BHI), based on type 2 diabetes patients from a prospective, multicentre, open label, non-controlled, observational, 24-week study. METHODS: A published and validated computer CORE Diabetes Model was used to project long-term economic and clinical outcomes in sub-cohort of type 2 diabetes patients treated with BIAsp 30 versus BHI 30. The cohort had 831 (372 male) patients. There was HbA1C decrease from 8.98 1.44% to 7.91 1.19% , decrease in BMI 0.26 1,36 kg/m 2 and reduction in major and minor hypoglycemic events by 97% and 80% respectively. Probabilities of complications, management costs adjustments (including complications) were derived from the Czech surveys from 2007. Treatment costs were from June 2009. Future costs and clinical benefits were discounted at 3.5 % per annum. RESULTS: The short-term benefits of switching from BHI 30 to BIAsp 30 are projected to lead to an increase in discounted quality-adjusted life expectancy of 0.493 years (4191 0.090 versus 3698 0.078). Increased total lifetime costs/patient is -CZK122,594 (534,259 1,9925 versus 65,7212 21,908) with BIAsp 30. Combining costs and clinical outcomes results in an incremental cost-effectiveness per qualityadjusted life year (QALYs) gained were dominant. CONCLUSIONS: CORE diabetes T2 patients sub-cohort simulation in 35 years perspective Czech observational study has demonstrated acceptable cost-effectiveness for patients with type 2 diabetes treated BIAsp 30. BIAsp 30 treatment was projected to be associated with improvements in life expectancy, QALYs and cost saving compared to BHI 30. Sensitivity analyses show cost-effectiveness result to be robust.
PDB25 A PATIENT-LEVEL SIMULATION MODEL FOR ECONOMIC EVALUATION OF CINACALCET IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN ITALY
Eandi M 1 , Pradelli L 2 , Iannazzo S 2 , Chiroli S 3 , Pontoriero G 4 1 Università degli Studi di Torino, Torino, Italy, 2 AdRes HE&OR, Torino, Italy, 3 Amgen, Zug, Switzerland, 4 Alessandro Manzoni Hospital, Lecco, Italy OBJECTIVES: Imbalanced levels of parathyroid hormone (PTH), serum calcium (Ca) and phosphorus (P) are associated with an increased risk of cardiovascular death and fracture. Cinacalcet can regulate these levels in patients with SHPT. Here we describe a cost-utility analysis of cinacalcet treatment in SHPT patients in Italy.
METHODS:
We developed a probabilistic patient-level simulation Markov model to simulate the effect of cinacalcet on individual Ca, P, and PTH levels (based on data of a European multicenter, open-label study); to correlate these levels with mortality and morbidity (cardiovascular events, fractures, and parathyroidectomies) recently published in two reviews; and to incorporate Italian data for dialysis patients and national cost structure. Simulation horizon was patient lifetime; simulated treatment alternatives were standard treatment (mainly vitamin D sterols and phosphate binders), and cinacalcet plus standard treatment. A 3.5% discount rate was applied to life expectancy (LE), quality-adjusted life expectancy (QALE), and costs and times in ranges (TiRs) recommended by the KDOQI initiative. Utilities were derived from a prospective cross sectional survey of 180 end-stage renal failure patients with and without co-morbidities. Costs were evaluated from the Italian National Healthcare Service perspective. RESULTS: Base case results were calculated with 10,000 iterations. Cinacalcet-treated patients had a mean (SD) increase in TiR of 5.60 (6.57), 3.45 (6.85), 1.62 (5.64) and 2.85 (5.60) discounted patient years for PTH, Ca, P, and all parameters, respectively. Mean LE extension was 1.16 (3.74) life-years and QALE increase 0.77 (2.63). The incremental cost-effectiveness ratio (ICER) calculated considering the TiR varied from a5,439 per patient-year in range to a18,748 per patient-year in range (limits for PTH and P, respectively). When considering LE, the average ICER results were a26,148/LY while when considering QALE, the average ICER was a39,454/quality-adjusted life year. CONCLUSIONS: Cinacalcet treatment could be considered cost-effective but further investigation is needed.
PDB26 THE PHARMACOECONOMIC STUDY OF INSULIN GLRAGINE USAGE IN ROUTINE CLINICAL PRACTICE IN RUSSIAN FEDERATION
Kolbin AS 1 , Shestakova MV 2
